NCT00838955终止2 期
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Loyola University1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
研究概览
简要总结
This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.
详细描述
Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed.
Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin Lymphoma with progressive disease during or at the end of the previous therapy, as defined by the IWG criteria.
- •Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin Lymphoma.
- •Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.
- •Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging.
- •A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at least 2 cm in diameter on a CT scan.
- •Patient should have had at least one line of prior chemotherapy. Patients relapsing after treatment with radiation therapy alone are not eligible.
- •Age > than or equal to 18 years.
- •Both men and women and members of all races and ethnic groups are eligible for this trial.
- •Women must not be pregnant or breast-feeding due to lack of information about the safety of administration of Temsirolimus in pregnant and lactating patients. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.
- •Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of pregnancy prevention.
- •Patient must have a SWOG performance status between 0-
- •Patient must have no prior treatment with an m-TOR inhibitor.
- •Patient must not have active infections at the time of registration.
- •Laboratory studies should be obtained within two weeks of study registration except where noted otherwise. Allowable laboratory values are listed below:
- •Absolute neutrophil count > than or equal 1,000/mm3
- •Hemoglobin > than or equal 8 gm/dL
- •Platelets > than or equal 75,000/mm3
- •Serum creatinine < than or equal to two times the upper limit of normal. Creatinine should be measured within seven days of registration.
- •Total serum bilirubin < than or equal to ≤ 1.5 times the upper limit of normal. Total bilirubin should be measured within seven days of registration.
- •AST (SGOT) < than or equal to 3 times the upper limit of normal.
- •ALT (SGPT) < than or equal to 3 times the upper limit of normal.
- •Fasting total cholesterol < than or equal to 350 mg/dL.
- •Fasting triglyceride level < than or equal to 400 mg/dL.
- •Patient must have a life expectancy of three months.
排除标准
- •Patient must not have received prior allogeneic stem cell transplantation. Prior autologous stem cell transplantation more than six months prior to registration is acceptable.
- •Patient must not have received prior chemotherapy, biologic therapy or radiation within three weeks prior to registration, and should have recovered from toxicities of prior therapy (to Grade 0 or 1).
- •Patient must not have evidence of active CNS disease.
- •Patient must not have an uncontrolled comorbid disease, including hyperlipidemia, hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- •Patient must not have a psychiatric illness or social situation that would limit compliance with study requirements.
- •Patient must have a life expectancy of three months.
研究组 & 干预措施
Temsirolimus
Experimental
Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
干预措施: Temsirolimus (Drug)
结局指标
主要结局
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
时间窗: 26 weeks
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
次要结局
- To evaluate the toxicity of temsirolimus in this patient population.(26 weeks)
- To estimate the time to progression after treatment with temsirolimus.(5 years)
- To estimate overall survival after treatment with temsirolimus.(5 years)
研究者
Hagen, Patrick A
Associate Professor
Loyola University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)Hodgkin LymphomaNCT05508867Merck Sharp & Dohme LLC203
已完成
2 期
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00547534University of Rochester31
Unknown
2 期
Temsirolimus in Recurrent Primary Central Nervous System (CNS) LymphomaRecurrent or Refractory Primary CNS LymphomaNCT00942747Charite University, Berlin, Germany37
招募中
1 期
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorNon Hodgkin LymphomaNCT04337606Chinese PLA General Hospital100
招募中
不适用
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data CollectionLymphoma, Non-HodgkinNCT06541327Ruijin Hospital1,000